Biocryst Pharmaceuticals Files Proxy Materials
Ticker: BCRX · Form: DEFA14A · Filed: Apr 25, 2024 · CIK: 882796
Sentiment: neutral
Topics: proxy-filing, sec-filing, corporate-governance
Related Tickers: BCRX
TL;DR
Biocryst filed more proxy docs, no new fees. Standard shareholder stuff.
AI Summary
Biocryst Pharmaceuticals Inc. filed a Definitive Additional Materials proxy statement on April 25, 2024. This filing is related to the company's proxy solicitation materials and does not involve a new proposal or a fee payment, as indicated by the 'No fee required' status.
Why It Matters
This filing indicates that Biocryst Pharmaceuticals is providing additional materials to shareholders related to proxy matters, which could pertain to upcoming shareholder meetings or votes.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, indicating standard corporate governance procedures rather than significant new risks.
Key Players & Entities
- BIOCRYST PHARMACEUTICALS INC (company) — Registrant
- 0001140361-24-022065 (filing_id) — Accession Number
- 20240425 (date) — Filing Date
FAQ
What type of filing is this?
This is a Definitive Additional Materials filing (DEFA14A) for Biocryst Pharmaceuticals, Inc.
When was this filing made?
The filing was made on April 25, 2024.
Is there a fee associated with this filing?
No, the filing indicates 'No fee required'.
What is the company's address?
The company's business and mailing address is 4505 Emperor Boulevard, Suite 200, Durham, NC 27703.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 121 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-04-25 16:24:13
Filing Documents
- ef20027731_defa14a.htm (DEFA14A) — 22KB
- image001.jpg (GRAPHIC) — 162KB
- image002.jpg (GRAPHIC) — 137KB
- 0001140361-24-022065.txt ( ) — 434KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 BIOCRYST PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.